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One-year risk of serious infection in
patients treated with certolizumab pegol
as compared with other TNF inhibitors in
a real-world setting: data from a national
U.S. rheumatoid arthritis registry
Leslie R. Harrold1,2*, Heather J. Litman2, Katherine C. Saunders2, Kimberly J. Dandreo2, Bernice Gershenson1,2,
Jeffrey D. Greenberg3, Robert Low4, Jeffrey Stark4, Robert Suruki5, Srihari Jaganathan4, Joel M. Kremer6
and Mohamed Yassine4
Abstract
Background: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor
inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety
outcomes without accounting for channeling bias can lead to inaccurate comparisons between TNFi prescribed
at different stages of the disease. In the present study, we examined the incidence of serious infection and other
adverse events during certolizumab pegol (CZP) use vs other TNFi in a U.S. RA cohort before and after using a
methodological approach to minimize channeling bias.
Methods: Patients with RA enrolled in the Corrona registry, aged ≥ 18 years, initiating CZP or other TNFi
(etanercept, adalimumab, golimumab, or infliximab) after May 1, 2009 (n = 6215 initiations), were followed for
≤ 12 months. A propensity score (PS) model was used to control for baseline characteristics associated with the
probability of receiving CZP vs other TNFi. Incidence rate ratios (IRRs) of serious infectious events (SIEs),
malignancies, and cardiovascular events (CVEs) in the CZP group vs other TNFi group were calculated with 95%
CIs, before and after PS matching.
Results: Patients were more likely to initiate CZP later in the course of therapy than those initiating other TNFi.
CZP initiators (n = 975) were older and had longer disease duration, more active disease, and greater disability
than other TNFi initiators (n = 5240). After PS matching, there were no clinically important differences between
CZP (n = 952) and other TNFi (n = 952). Before PS matching, CZP was associated with a greater incidence of SIEs
(IRR 1.53 [95% CI 1.13, 2.05]). The risk of SIEs was not different between groups after PS matching (IRR 1.26
[95% CI 0.84, 1.90]). The 95% CI of the IRRs for malignancies or CVEs included unity, regardless of PS matching,
suggesting no difference in risk between CZP and other TNFi.
Conclusions: After using PS matching to minimize channeling bias and compare patients with a similar likelihood
of receiving CZP or other TNFi, the 1-year risk of SIEs, malignancies, and CVEs was not distinguishable between the
two groups.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that causes persistent synovial inflammation. When
not treated adequately, active RA can lead to progressive
joint damage, significant pain, disability, and reduced
quality of life [1, 2]. The chronic inflammation inherent
to RA has consequences that go beyond the damage to
the musculoskeletal system. Compared with the general
population, RA is associated with substantial morbidity
and premature mortality, which is attributed mainly to
serious infection, cardiovascular disease, and certain
types of cancer [3–5]. The substantial disease burden of
RA underscores the importance of effective therapy.
Tumor necrosis factor inhibitors (TNFi), often the first
class of biologic therapy prescribed to patients with RA,
have been demonstrated to reduce disease activity and
improve clinical, radiographic, and functional outcomes
[6]. Effective control of disease activity with TNFi has
been linked with a reduced risk of cardiovascular disease
[7, 8]. Conversely, the immunosuppressive effect of TNFi
has raised concerns over an increased risk of infection
[9], although the magnitude of this risk remains a topic
of intense debate [10–21]. The impact of TNFi on the
incidence of cancer is also unclear [11, 22–25].
Overall, it is difficult to assess the risks associated with
TNFi therapy, owing to the influence of patients’ demo-
graphic characteristics, clinical history, and concomitant
immunomodulatory treatments. Furthermore, in clinical
practice, drugs with similar therapeutic indications can
be prescribed selectively to patients with different base-
line prognoses, a phenomenon termed channeling bias
[26]. Consequently, the line of TNFi therapy may also
influence the safety risks observed in clinical practice.
Certolizumab pegol (CZP), a PEGylated, Fc-free TNFi,
is approved for the treatment of adult patients with
moderate to severe active RA [27]. Currently, there is
limited evidence on the safety of CZP compared with
other TNFi drugs in the context of U.S. clinical practice.
The objective of this prospective, observational cohort
study was to examine the 1-year incidence of serious in-
fectious events (SIEs) during CZP use compared with
other TNFi drugs (golimumab, etanercept, adalimumab,
and infliximab), with and without a methodological ap-
proach accounting for channeling bias in patients with
moderate to severe RA enrolled in the Consortium of
Rheumatology Researchers of North America (Corrona)
registry. The 1-year risk of malignancies and cardiovas-
cular events (CVEs) was also assessed, owing to their
importance for decision-making in clinical practice.
Methods
Data source
The Corrona registry is an independent, prospective, ob-
servational cohort of patients with RA recruited from
169 private and academic practice sites across 40 states
in the United States [28]. Data on 43,099 patients with
RA had been collected as of June 30, 2016. The Corrona
database comprises information from 326,613 patient
visits and approximately 145,526.5 patient-years (PY) of
total follow-up, with a mean patient follow-up of
4.13 years, and median time between follow-up visits of
4.90 months. Institutional review board (IRB) approvals
for this study were obtained from a central IRB (New
England IRB) for private practice sites and local IRBs of
participating academic sites.
Study population
Data were provided by treating rheumatologists for pa-
tients with RA enrolled in the Corrona registry who ini-
tiated treatment with CZP or other TNFi (adalimumab,
etanercept, golimumab, and infliximab) between May 1,
2009, and March 31, 2016. Patients could have been
treated with TNFi before this study, so index drug corre-
sponded to any line of therapy. If patients were treated
with more than one TNFi during the study, all TNFi ini-
tiations were included in the analysis. The study popula-
tion comprised patients aged ≥ 18 years with at least one
follow-up visit post-drug initiation. All patients provided
written informed consent prior to participation.
Adverse events of interest
Physician-reported adverse events (AEs) of interest that
occurred from drug initiation up to 90 days following
discontinuation/switch of TNFi, or up to 12 months
from drug initiation, were included in the analysis. SIEs
were the main AE of interest (infections requiring
hospitalization and/or intravenous antibiotics); when
data were available, information was also provided about
the SIE microorganism (opportunistic vs nonopportunis-
tic), malignancies, and CVEs (Table 1).
Other AEs of interest included anaphylaxis/allergic reac-
tion, drug-induced systemic lupus erythematosus, gastro-
intestinal perforation, hepatic events, progressive
multifocal leukoencephalopathy, other neurological events
with hospitalization and/or other demyelinating disease,
and spontaneous serious bleeding (see Additional file 1:
Table S1). Corrona has an established system for the valid-
ation of physician-reported AEs. Briefly, serious AEs and
AEs of special interest are recorded by treating physicians
using Targeted Adverse Event questionnaires. These ques-
tionnaires, alongside supporting documents appropriate
to the event (e.g., hospitalization records, pathology re-
ports), are submitted to Corrona for validation, with a
subset triaged for expert adjudication. Previous validation
of Corrona’s AE reporting has found positive predictive
values of 86% for malignancies [29], 96% for CVEs [30],
and 71% for SIEs [31].
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Propensity score matching
To control for baseline patient characteristics associated
with the likelihood of receiving CZP or an alternative
TNFi, a propensity score (PS; i.e., the probability of
treatment selection) was calculated for each patient
using a logistic regression model that included baseline
covariates with p < 0.1 for the difference between CZP
and other TNFi and thought to be independently associ-
ated with treatment on the basis of clinical expertise and
prior group consensus. CZP and other TNFi patients
were matched by estimated PS from a model including
age, sex, disease duration, Clinical Disease Activity Index
(CDAI) at drug initiation, and physician-reported line of
TNFi therapy. Matching was performed in a 1:1 ratio
without replacement, using a maximum tolerated differ-
ence (caliper) of 0.01.
Statistical analysis
Patients’ comorbidity scores were calculated using a
modified version of the Charlson comorbidity index [32]
(see Additional file 1). All patients had a modified
Charlson comorbidity index ≥ 1 because RA is included
under connective tissue disease.
Baseline characteristics were compared between CZP
and other TNFi patients before and after PS matching.
Student’s two-sample t tests were used for continuous
variables (or Wilcoxon rank-sum tests if variables were
skewed), and chi-square tests were used for categorical
variables (or Fisher’s exact test in the case of small
counts). All p values were nominal in nature and should
be interpreted in an exploratory manner.
Observed incidence rates (IRs) of AEs of interest were
calculated per 100 PY, with 95% CIs calculated using the
Poisson distribution assumption. For each AE category,
time at risk was measured from drug initiation up to ei-
ther the occurrence of the first event of interest under that
category, 90 days following discontinuation/switch of bio-
logic (censored), or up to 12 months after drug initiation
(censored). Incidence rate ratios (IRRs) were calculated in
both unmatched and PS-matched comparisons for overall
SIEs, malignancies, and CVEs, with CZP as numerator
and other TNFi as denominator; 95% CIs were calculated
using the exact distribution derived using Stata® version
14.1 software (StataCorp LP, College Station, TX, USA).
Results
Baseline demographics
A total of 5363 patients with RA in the Corrona data-
base met the inclusion criteria and initiated TNFi ther-
apy between May 1, 2009, and March 31, 2016. There
were a total of 6215 TNFi initiations comprising 975
CZP initiators and 5240 initiators of other TNFi (adali-
mumab, etanercept, golimumab, and infliximab). After
PS matching, the CZP and other TNFi groups included
952 patients each (Fig. 1).
Among all initiators (before PS matching), on average,
patients initiating CZP were older, had longer disease
duration, had more active disease based on the CDAI,
and had more functional impairment based on the
modified Health Assessment Questionnaire than pa-
tients in the other TNFi group (p ≤ 0.01) (Table 2). Race
and Medicare insurance status also showed an imbalance
between the two groups (p < 0.001). Sex, body mass
index (BMI), age at RA onset, and the prevalence of co-
morbidities were balanced between groups (Table 2), as
were rheumatoid factor positivity, anticitrullinated pro-
tein antibody positivity, smoking status, and blood pres-
sure (not shown). Patients were more likely to initiate
CZP later in the course of therapy, with approximately
44.8% of CZP initiators corresponding to third-line ther-
apy or later, compared with 20.1% in the other TNFi
group (Table 2). Concomitant disease-modifying anti-
rheumatic drug (DMARD) and prednisone use were
similar between the two groups, except for methotrexate
(MTX) and other nonbiologic DMARD use, which was
more prevalent among other TNFi initiators (Table 2).
After PS matching, there were no clinically relevant
baseline differences between the CZP and other TNFi
groups; line of TNFi therapy and concomitant medica-
tion use were also similar (Table 2).
Table 1 Adverse events of interest
AE category Physician-reported AEs included in the analysis
SIEs Infections for which the patient was hospitalized
and/or received intravenous antibiotics, which
were categorized as follows: joint/bursa,
cellulitis/skin, sinusitis, diverticulitis, sepsis,
pneumonia, bronchitis, gastroenteritis,
meningitis/encephalitis, urinary tract infection,
upper respiratory infection, active tuberculosis
(latent tuberculosis infection was not included),
and other infections
SIE microorganism Opportunistic infections: coccidioidomycosis,
Cryptococcus, herpes zoster, histoplasmosis,
John Cunningham virus, Listeria, Pneumocystis,
active tuberculosis (latent tuberculosis infection
was not included), and other opportunistic
infections. Nonopportunistic infections:
methicillin-resistant Staphylococcus aureus (MRSA),
bacterial infection other than MRSA, and other
nonopportunistic infections
Malignancies Nonmelanoma skin cancer, melanoma skin cancer,
lymphoma, breast cancer, lung cancer, and other
cancers
CVEs Myocardial infarction, transient ischemic attack,
stroke, congestive heart failure with hospitalization,
cardiac revascularization procedure, ventricular
arrhythmia, cardiac arrest, acute coronary syndrome,
unstable angina, hypertension with hospitalization,
peripheral arterial thromboembolic event, urgent
peripheral arterial revascularization, peripheral
ischemia or gangrene (necrosis), and other CVEs
Abbreviations: AE Adverse event, SIE Serious infection event,
CVE Cardiovascular event
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Observed incidence of AEs in the unmatched population
Average follow-up for each of the AEs can be calculated
as the number of PY at risk divided by the number of
patients considered. For instance, with SIEs in the CZP
group, the average follow-up time was 820/975 = 0.84
PY (approximately 10 months).
Among all initiators, the IR of SIEs was higher in the
CZP group than in the other TNFi group (Table 3). The
95% CI of the corresponding IRR excluded unity (IRR
1.53 [1.13, 2.05]), suggesting that CZP was associated
with a greater risk of SIEs than other TNFi (Fig. 2a). By
contrast, the IRs of malignancies and CVEs did not dif-
fer substantially between CZP and other TNFi (Table 3).
The 95% CI of the IRRs for malignancies (IRR 0.86
[0.46, 1.49]) and CVEs (IRR 1.22 [0.67, 2.08]) included
unity, suggesting no difference in risk between the two
groups (Fig. 2a).
Cellulitis/skin infection, pneumonia, and urinary tract
infection were the most frequently reported SIEs. There
were no cases of active tuberculosis among CZP initia-
tors, and there were two cases in the other TNFi group
(Table 3). Regarding other AEs of interest, rare cases of
anaphylaxis/allergic reaction were reported for both
CZP (4 events) and other TNFi (14 events). Patients in
the other TNFi group also reported gastrointestinal
perforation (three events), hepatic events (ten events),
other neurological events (four events), and spontan-
eous serious bleeding (five events) (Table 3).
Observed incidence of AEs in the PS-matched population
In contrast with the unmatched population, the IR of
SIEs was similar between CZP and other TNFi after PS
matching (Table 4). The 95% CI of the IRR included
unity (IRR 1.26 [0.84, 1.90]), suggesting that the risk of
SIEs was not different between the PS-matched groups
(Fig. 2b). Similar to what was seen in the unmatched
population, the IRs of malignancies and CVEs in the
CZP and other TNFi groups did not differ substantially
after PS matching (Table 4). The 95% CI of the IRRs for
malignancies (IRR 0.71 [0.33, 1.47]) and CVEs (IRR 1.01
[0.49, 2.11]) included unity, suggesting no difference in
risk between the PS-matched groups (Fig. 2b).
Cellulitis/skin infection, pneumonia, and urinary tract
infection were still the most frequent SIEs. The inci-
dence rates of other AEs of interest remained low in the
PS-matched groups (Table 4).
Discussion
When initiating TNFi therapy in RA, rheumatologists
need to carefully balance the potential clinical benefits
of treatment with the anticipated risks in each individ-
ual patient in light of their demographic characteristics,
clinical history, and concomitant medications. Except-
ing a recently completed head-to-head randomized
controlled trial (RCT) comparing the efficacy and safety
of CZP and adalimumab, in which investigators re-
ported no clinically significant differences between the
Fig. 1 Patient disposition. Data from May 1, 2009, through March 31, 2016, were available. There were 975 unique CZP patients and 4625 unique other
TNFi patients. aEligible patients with RA were≥ 18 years of age, had at least one follow-up visit post-index drug initiation, and provided written informed
consent prior to participation. bInitiations refer to the total number of TNFi initiated during the period of observation because patients may have used
more than one TNFi during the study (e.g., if one patient switched from etanercept to CZP, both initiations would have been included in the analysis).
cPropensity scores were calculated using a logistic regression model fitted with the following baseline covariates: age, sex, disease duration, CDAI at
initiation, and TNFi line of therapy. RA rheumatoid arthritis, CZP certolizumab pegol, TNFi tumor necrosis factor inhibitor, IV intravenous, CDAI Clinical
Disease Activity Index
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Table 2 Baseline demographics, disease characteristics, tumor necrosis factor inhibitor line of therapy, and concomitant medications,
before and after propensity score matching
Before PS matching After PS matching
CZP (n = 975) Other TNFi
(n = 5240)
Nominal
p value
CZP (n = 952) Other TNFi
(n = 952)
Nominal
p value
Demographics
Age, years, median (IQR) 58 (18.0) 56 (16.5) < 0.001 58 (17.0) 58 (16.0) 0.48
Female sex, n (%) 769 (78.9) 4107 (78.4) 0.74 751 (78.9) 750 (78.8) 0.96
Race, white, n (%) 840 (86.2) 4310 (82.3) < 0.001 820 (86.1) 786 (82.6) 0.03a
BMI, kg/m2, mean (SD) 30.0 (7.3) 30.1 (7.3) 0.49 30.0 (7.3) 30.1 (7.5) 0.68
Insuranceb
Medicare, n (%) 321 (32.9) 1363 (26.0) < 0.001 315 (33.1) 293 (30.8) 0.28
Medicaid, n (%) 48 (4.9) 327 (6.2) 0.12 48 (5.0) 59 (6.2) 0.32
Private, n (%) 712 (73.0) 4034 (77.0) 0.01 700 (73.5) 719 (75.5) 0.32
None, n (%) 23 (2.4) 136 (2.6) 0.74 22 (2.3) 14 (1.5) 0.24
Clinical characteristics
Age at RA onset, years, mean (SD) 46.9 (14.4) 47.4 (13.5) 0.35 47.0 (14.4) 46.7 (13.8) 0.73
Disease duration, years, median (IQR) 9 (12.0) 5 (10.0) < 0.001 9 (12.0) 8 (12.5) 0.26
CDAI, median (IQR) 19.0 (20.2) 17.0 (19.0) 0.01 19.0 (20.2) 18.5 (20.0) > 0.99
mHAQ, median (IQR) 0.5 (0.8) 0.4 (0.8) < 0.001 0.5 (0.8) 0.5 (0.8) 0.89
History of comorbidities
Diabetes, n (%) 75 (7.7) 467 (8.9) 0.22 75 (7.9) 96 (10.1) 0.09
Pulmonary disease,c n (%) 58 (5.9) 347 (6.6) 0.43 58 (6.1) 64 (6.7) 0.57
Cardiovascular disease,d n (%) 57 (5.8) 283 (5.4) 0.57 54 (5.7) 57 (6.0) 0.77
Malignancy,e n (%) 48 (4.9) 225 (4.3) 0.38 46 (4.8) 45 (4.7) 0.91
Serious infection,f n (%) 64 (6.6) 348 (6.6) 0.93 63 (6.6) 80 (8.4) 0.14
Comorbidity indexg
Median score (IQR) 1 (0) 1 (0) 0.60 1 (0) 1 (0) 0.12
Score ≥ 2, n (%) 197 (21.1) 1029 (20.3) 0.60 191 (20.9) 216 (23.7) 0.16
Line of TNFi therapy < 0.001h 0.69h
First, n (%) 253 (25.9) 2594 (49.5) 250 (26.3) 236 (24.8)
Second, n (%) 285 (29.2) 1593 (30.4) 276 (29.0) 290 (30.5)
Third or later, n (%) 437 (44.8) 1053 (20.1) 426 (44.7) 426 (44.7)
Concomitant DMARD use
Nonbiologic DMARDs (excluding MTX), n (%) 146 (15.0) 819 (15.6) 0.60 143 (15.0) 166 (17.4) 0.15
MTX and other nonbiologic DMARDs, n (%) 85 (8.7) 661 (12.6) < 0.001 84 (8.8) 105 (11.0) 0.11
MTX (excluding other nonbiologic DMARDs), n (%) 469 (48.0) 2597 (49.6) 0.40 456 (47.9) 450 (47.3) 0.78
Concomitant prednisone use 0.45h 0.26h
None, n (%) 679 (70.1) 3695 (70.9) 661 (69.9) 658 (69.3)
< 10 mg/day, n (%) 197 (20.4) 982 (18.8) 193 (20.4) 179 (18.9)
≥ 10 mg/day, n (%) 92 (9.5) 538 (10.3) 91 (9.6) 112 (11.8)
Abbreviations: CZP Certolizumab pegol, TNFi Tumor necrosis factor inhibitor, PS Propensity score, BMI Body mass index, RA Rheumatoid arthritis, CDAI Clinical
Disease Activity Index, mHAQ, Modified Health Assessment Questionnaire (disability index), COPD Chronic obstructive pulmonary disease, NMSC Nonmelanoma
skin cancer, DMARD Disease-modifying antirheumatic drug, MTX Methotrexate
aRace was statistically different between the PS-matched groups (p = 0.03), but this was not thought to be clinically significant
bInsurance categories were not mutually exclusive; therefore, patients could be captured in more than one category
cPulmonary disease included asthma, COPD, and interstitial lung disease/pulmonary fibrosis
dCardiovascular disease included coronary artery disease, myocardial infarction, coronary heart failure requiring hospitalization, acute coronary syndrome, unstable
angina, cardiac revascularization procedure, cardiac arrest, ventricular arrhythmia, and other cardiovascular diseases
eMalignancy included lung cancer, breast cancer, melanoma skin cancer, and other cancers
fSerious infection was defined as any infection for which the patient was hospitalized and/or received intravenous antibiotics
gComorbidity index was a modified version of the Charlson comorbidity index and corresponded to the sum of scores for current and physician-reported prior
comorbid conditions, namely myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease (captured as stroke or transient
ischemic attack), COPD, history of bleeding and/or peptic ulcer, diabetes mellitus, leukemia, lymphoma, solid tumor cancer (excluding nonmelanoma skin cancer
[NMSC]), liver disease, and connective tissue disease (including RA, so all patients had a comorbidity index ≥ 1)
hp Values were based on chi-square tests to ascertain if the overall distribution differed significantly between the CZP and other TNFi groups
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Table 3 Rates of adverse events of interest before propensity score matching (all initiators)
CZP (n = 975) Other TNFi (n = 5240)
PY at riska Eventsb IR/100 PY
(95% CI)
PY at riska Eventsb IR/100 PY
(95% CI)
Serious infectious events 820 59 7.20 (5.58, 9.29) 4566 215 4.71 (4.12, 5.38)
Joint/bursa 847 2 0.24 (0.06, 0.94) 4660 16 0.34 (0.21, 0.56)
Cellulitis/skin 841 13 1.55 (0.90, 2.66) 4650 36 0.77 (0.56, 1.07)
Sinusitis 847 2 0.24 (0.06, 0.94) 4660 10 0.21 (0.12, 0.40)
Diverticulitis 847 2 0.24 (0.06, 0.94) 4660 10 0.21 (0.12, 0.40)
Sepsis 848 1 0.12 (0.02, 0.84) 4657 16 0.34 (0.21, 0.56)
Pneumonia 842 15 1.78 (1.07, 2.95) 4641 58 1.25 (0.97, 1.62)
Bronchitis 846 5 0.59 (0.25, 1.42) 4660 11 0.24 (0.13, 0.43)
Gastroenteritis 847 4 0.47 (0.18, 1.26) 4659 14 0.30 (0.18. 0.51)
Meningitis/encephalitis 848 0 0 (NC) 4665 2 0.04 (0.01, 0.17)
Urinary tract infection 842 10 1.19 (0.64, 2.21) 4650 29 0.62 (0.43, 0.90)
Upper respiratory infection 848 2 0.24 (0.06, 0.94) 4660 10 0.21 (0.12, 0.40)
Active tuberculosisc 848 0 0 (NC) 4664 2 0.04 (0.01, 0.17)
Other 844 9 1.07 (0.55, 2.05) 4649 36 0.77 (0.56, 1.07)
Identified serious infectious organism 839 15 1.79 (1.08, 2.96) 4636 65 1.40 (1.10, 1.79)
Opportunistic 848 0 0.00 (NC) 4664 2 0.04 (0.01, 0.17)
Nonopportunistic 843 8 0.95 (0.47, 1.90) 4648 30 0.65 (0.45, 0.92)
Unknown 844 7 0.83 (0.40, 1.74) 4648 34 0.73 (0.52, 1.02)
Malignancies 841 15 1.78 (1.08, 2.96) 4622 96 2.08 (1.70, 2.54)
Lymphoma 848 0 0 (NC) 4664 4 0.09 (0.03, 0.23)
Breast cancer 848 1 0.12 (0.02, 0.84) 4660 9 0.19 (0.10, 0.37)
Lung cancer 848 2 0.24 (0.06, 0.94) 4664 3 0.06 (0.02, 0.20)
Skin cancer – melanoma 848 0 0 (NC) 4662 6 0.13 (0.06, 0.29)
Skin cancer – basal/squamous 845 5 0.59 (0.25, 1.42) 4641 49 1.06 (0.80, 1.40)
Other cancer 844 7 0.83 (0.40, 1.74) 4655 26 0.56 (0.38, 0.82)
Cardiovascular events 840 17 2.02 (1.26, 3.26) 4633 77 1.66 (1.33, 2.08)
Myocardial infarction 847 3 0.35 (0.11, 1.10) 4661 11 0.24 (0.13, 0.43)
TIA/stroke 846 5 0.59 (0.25, 1.42) 4650 34 0.73 (0.52, 1.02)
Other cardiovascular eventd 843 10 1.19 (0.64, 2.20) 4649 43 0.93 (0.69, 1.25)
Other AEs of interest
Anaphylaxis/allergic reaction 845 4 0.47 (0.18, 1.26) 4660 14 0.30 (0.18, 0.51)
Drug-induced SLE 848 0 0 (NC) 4665 0 0 (NC)
Gastrointestinal perforation 848 0 0 (NC) 4663 3 0.06 (0.02, 0.20)
Hepatic event 848 0 0 (NC) 4660 10 0.21 (0.12, 0.40)
Progressive multifocal leukoencephalopathy 848 0 0 (NC) 4665 0 0 (NC)
Other neurological event (with hospitalization)
/other demyelinating disease
848 0 0 (NC) 4664 4 0.09 (0.03, 0.23)
Spontaneous serious bleeding 848 0 0 (NC) 4664 5 0.11 (0.04, 0.26)
Abbreviations: AE Adverse events, PS Propensity score, CZP Certolizumab pegol, TNFi Tumor necrosis factor inhibitor, PY Patient-years,
IR Incidence rate, NC Not calculable, CVE Cardiovascular event, TIA Transient ischemic attack, SLE Systemic lupus erythematosus
aTime at risk was measured from drug initiation up to either the occurrence of the first event of interest under that category, 90 days following
discontinuation/switch of TNFi, or up to 12 months after drug initiation
bPatients may have experienced more than one AE, so the sum of individual conditions may be greater than the total number of first AEs for the
overall categories; however, only the time to the first event was considered to calculate the corresponding IRs
cLatent tuberculosis was not included
dIncluded congestive heart failure with hospitalization, cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, acute coronary
syndrome, unstable angina, hypertension with hospitalization, peripheral arterial thromboembolic event, urgent peripheral arterial revascularization,
peripheral ischemia or gangrene (necrosis), and other CVEs
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two drugs [33], there is a paucity of head-to-head RCTs
comparing the safety of TNFi drugs in RA. Observa-
tional studies therefore provide a valuable source of
comparative safety data.
Using data from the Corrona registry, we compared the
safety of CZP with other TNFi as a group (golimumab,
etanercept, adalimumab, and infliximab). As with any
registry study, channeling bias can arise from the fact that
clinicians prescribe treatment not at random but based on
personal clinical experience and their patients’ clinical
characteristics [26]. To overcome this limitation, we
assessed safety outcomes in two cohorts: (1) all patients
initiating CZP or other TNFi therapy and (2) the subset of
patients matched by PS. In the unmatched population, the
rate of SIEs was approximately 50% higher in the CZP
group than in the other TNFi group. After using the PS-
matched model to minimize channeling bias and resolve
clinically significant baseline differences between CZP and
other TNFi initiators, the risk of SIEs associated with each
group was no longer distinguishable.
The contrasting results in the unmatched and PS-
matched cohorts highlight the need to consider baseline
patient differences when comparing the risk of AEs be-
tween TNFi drugs prescribed at different stages in the
course of RA. CZP was prescribed later in the line of
therapy than other TNFi. Consequently, patients initiat-
ing CZP were, on average, older and had longer disease
duration, more active disease, and more functional im-
pairment than patients initiating treatment with other
TNFi. This probably explains the higher rate of SIEs in
the unmatched CZP group because older age, high dis-
ease activity, and disability have previously been identi-
fied as risk factors for serious infection in RA [9, 34–38].
Meta-analyses of RCTs have demonstrated that the dif-
ferent TNFi drugs available in RA are equally efficacious
at reducing disease activity [18]. Therefore, on the basis
of clinical efficacy alone, there has been relative equi-
poise among rheumatologists regarding which therapy
to choose as first and subsequent lines of treatment [39].
However, the safety of TNFi therapy, particularly with
regard to infection, continues to be debated. The authors
of the first published meta-analysis of serious infection
in RA detected an association with TNFi treatment
[11], but subsequent meta-analyses performed with
greater sample sizes have produced discordant results
[14, 15, 17, 18, 20]. Similarly, whereas researchers in
some observational studies have reported an association
between TNFi and the risk of serious infection [10, 13, 19],
others did not find a clear link [12, 16, 21]. In a large
meta-analysis of RCTs in which authors compared the
safety of all five TNFi drugs across multiple diseases, CZP
was associated with higher odds of serious infection than
adalimumab, etanercept, and golimumab [40]. However,
the diseases and patient populations captured in this
meta-analysis differed substantially between drugs, and no
correction was made for placebo exposure, which makes
the results difficult to interpret. It is known that the back-
ground risk of SIEs varies greatly across diseases [37, 41],
and even within indications it is strongly dependent on
study inclusion criteria and baseline patient characteristics
[35]. By contrast, a recent head-to-head clinical trial com-
paring the efficacy and safety of CZP with adalimumab in
patients with RA provided direct evidence of a comparable
safety profile for the two drugs, including a similar inci-
dence of serious infection [33].
The IRs of SIEs reported in the present study are con-
sistent with rates observed in other real-world patient
populations. For example, in a retrospective study of
medical and pharmaceutical data from a large U.S.
health insurer, the rate of hospitalized infections among
patients with RA with no prior biologic use was 4.6/100
PY, whereas for patients switching to a new biologic at
baseline, an IR of 7.0/100 PY was reported [35]. In a
retrospective analysis of Medicare claims data for pa-
tients with RA treated with prior biologics, the crude
IRs of hospitalized infection during TNFi treatment
ranged between 14.1/100 PY (golimumab) and 17.0/100
PY (infliximab; the IR for CZP was 14.2/100 PY) [42]. A
prospective observational study using data from the
British Society for Rheumatology Biologics Register –
Rheumatoid Arthritis (BSRBR-RA) reported rates of SIEs
ranging from 2.8/100 PY in patients aged < 55 years to
8.3/100 PY in patients aged > 75 years [13].
Regardless of PS matching, there were no important
differences in the IRs of malignancies and CVEs between
CZP and other TNFi initiators. Interpretation of these
results must take into account the infrequent nature of
Fig. 2 IRRs of SIEs, malignancies, and CVEs between the CZP and other
TNFi groups. a Before PS matching (all initiators). b After PS matching.
IRRs were calculated with the CZP group in the numerator and the
other TNFi in the denominator. IRR Incidence rate ratio, SIE Serious
infectious event, CVE Cardiovascular event, CZP Certolizumab pegol,
TNFi Tumor necrosis factor inhibitor, PS Propensity score
Harrold et al. Arthritis Research & Therapy  (2018) 20:2 Page 7 of 11
Table 4 Rates of adverse events of interest after propensity score matching
CZP (n = 952) Other TNFi (n = 952)
PY at riska Eventsb IR/100 PY (95% CI) PY at riska Eventsb IR/100 PY (95% CI)
Serious infectious events 799 57 7.13 (5.50, 9.25) 814 46 5.65 (4.23, 7.54)
Joint/bursa 825 2 0.24 (0.06, 0.97) 836 3 0.36 (0.12, 1.11)
Cellulitis/skin 820 13 1.59 (0.92, 2.73) 833 9 1.08 (0.56, 2.08)
Sinusitis 826 2 0.24 (0.06, 0.97) 835 2 0.24 (0.06, 0.96)
Diverticulitis 826 2 0.24 (0.06, 0.97) 835 2 0.24 (0.06, 0.96)
Sepsis 826 1 0.12 (0.02, 0.86) 836 3 0.36 (0.12, 1.11)
Pneumonia 821 15 1.83 (1.10, 3.03) 833 9 1.08 (0.56, 2.08)
Bronchitis 825 5 0.61 (0.25, 1.46) 835 2 0.24 (0.06, 0.96)
Gastroenteritis 825 4 0.48 (0.18, 1.29) 834 5 0.60 (0.25, 1.44)
Meningitis/encephalitis 827 0 0 (NC) 837 1 0.12 (0.02, 0.85)
Urinary tract infection 821 10 1.22 (0.66, 2.26) 834 6 0.72 (0.32, 1.60)
Upper respiratory infection 827 2 0.24 (0.06, 0.97) 835 3 0.36 (0.12, 1.11)
Active tuberculosisc 827 0 0 (NC) 837 1 0.12 (0.02, 0.85)
Other 823 7 0.85 (0.41, 1.78) 832 9 1.08 (0.56, 2.08)
Identified serious infection organism 819 14 1.71 (1.01, 2.89) 831 14 1.69 (1.00, 2.85)
Opportunistic 827 0 0 (NC) 836 2 0.24 (0.06, 0.96)
Nonopportunistic 822 8 0.97 (0.49, 1.95) 835 4 0.48 (0.18, 1.28)
Unknown 824 6 0.73 (0.33, 1.62) 834 8 0.96 (0.48, 1.92)
Malignancies 821 14 1.71 (1.01, 2.88) 827 20 2.42 (1.56, 3.75)
Lymphoma 827 0 0 (NC) 836 2 0.24 (0.06, 0.96)
Breast cancer 827 1 0.12 (0.02, 0.86) 837 0 0 (NC)
Lung cancer 827 2 0.24 (0.06, 0.97) 837 0 0 (NC)
Skin cancer – melanoma 827 0 0 (NC) 836 2 0.24 (0.06, 0.96)
Skin cancer – basal/squamous 825 4 0.48 (0.18, 1.29) 833 8 0.96 (0.48, 1.92)
Other cancer 823 7 0.85 (0.41, 1.78) 833 8 0.96 (0.48, 1.92)
Cardiovascular events 819 17 2.08 (1.29, 3.34) 829 17 2.05 (1.27, 3.30)
Myocardial infarction 825 3 0.36 (0.12, 1.13) 837 1 0.12 (0.02, 0.85)
TIA/stroke 824 5 0.61 (0.25, 1.46) 832 10 1.20 (0.65, 2.23)
Other cardiovascular eventd 822 10 1.22 (0.65, 2.26) 833 9 1.08 (0.56, 2.08)
Other AEs of interest
Anaphylaxis/allergic reaction 824 4 0.49 (0.18, 1.29) 835 5 0.60 (0.25, 1.44)
Drug-induced SLE 827 0 0 (NC) 837 0 0 (NC)
Gastrointestinal perforation 827 0 0 (NC) 837 1 0.12 (0.02, 0.85)
Hepatic event 827 0 0 (NC) 834 4 0.48 (0.18, 1.28)
Progressive multifocal leukoencephalopathy 827 0 0 (NC) 837 0 0 (NC)
Other neurological event (with hospitalization)
/other demyelinating disease
827 0 0 (NC) 837 0 0 (NC)
Spontaneous serious bleeding 827 0 0 (NC) 837 1 0.12 (0.02, 0.85)
Abbreviations: AE Adverse events, PS Propensity score, CZP Certolizumab pegol, TNFi Tumor necrosis factor inhibitor, PY Patient-years, IR Incidence rate,
NC Not calculable, CVE Cardiovascular event, TIA Transient ischemic attack, SLE Systemic lupus erythematosus
aTime at risk was measured from drug initiation up to either the occurrence of the first event of interest under that category, 90 days following
discontinuation/switch of TNFi, or up to 12 months after drug initiation
bPatients may have experienced more than one AE, so the sum of individual conditions may be greater than the total number of first AEs for the
overall categories; however, only the time to the first event was considered to calculate the corresponding IRs
cLatent tuberculosis was not included
dIncluded congestive heart failure with hospitalization, cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, acute coronary
syndrome, unstable angina, hypertension with hospitalization, peripheral arterial thromboembolic event, urgent peripheral arterial revascularization,
peripheral ischemia or gangrene (necrosis), and other CVEs
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these AEs and the fact that patients in this study were
followed for a maximum of 12 months, which may have
been too short to detect meaningful risk differences
between groups.
Evaluating the impact of TNFi on the risk of cancer in
RA is a challenging task. Because most types of cancer
occur very rarely, RCTs often lack sufficient power to
conclusively assess the risk of malignancy, owing to the
short duration of follow-up. Furthermore, patients with
RA with a history of cancer tend to be excluded from
participation in RCTs [43]. Given the latency of cancer
and its potential for reactivation over time, it is import-
ant to evaluate the risks of TNFi use in patients with a
history of this condition. Approximately 5% of Corrona
patients included in our study had a history of prior ma-
lignancy. Regardless of PS matching, the IRs of malig-
nancies reported here for CZP and other TNFi initiators
were comparable to those previously reported in the
BSRBR-RA [43, 44] and the Swedish Biologics Registry
[45]. Also consistent with these two registries, nonmela-
noma skin cancer was one of the most commonly re-
ported malignancies [46, 47].
Cardiovascular disease is one of the main causes of
morbidity and premature mortality in patients with RA
[3]. This has been attributed to the direct impact of
chronic inflammation on the vascular system and to the
secondary effects of physical inactivity [48]. By effectively
reducing disease activity, TNFi treatment may help to
mitigate the cardiovascular risk associated with RA
[7, 8]. In this study, traditional cardiovascular risk
factors such as BMI, smoking status, blood pressure,
history of cardiovascular disease, and prednisone use
were similar at drug initiation between the CZP and other
TNFi groups. By contrast, RA disease activity, which is
also associated with cardiovascular risk [8, 49, 50], was
higher in the CZP group. Nevertheless, the IRs of CVEs
we report, which corresponded mainly to myocardial in-
farction and transient ischemic attack (TIA)/stroke, did
not differ substantially between the CZP and other TNFi
groups, regardless of PS matching.
A limitation of this study was that patients were
followed for a maximum of 12 months after initiation of
a particular TNFi. Although SIE rates tend to be highest
during the first 6–12 months of TNFi exposure [13, 51],
this time frame may not have been sufficient to detect
differences in the rates of CVEs or malignancies, owing
to the comparative infrequency and longer-term nature
of these AEs. Despite this limitation, the rates of malig-
nancy we report were consistent with a recent meta-
analysis of observational studies where there were no
differences among the five TNFi drugs regarding the
overall risk of cancer [52]. Similarly, the rates of myocar-
dial infarction and TIA/stroke were comparable to those
previously reported for the Corrona cohort [8]. The
rarity of other AEs of interest prevented further analyses;
their inclusion in this report was meant to provide a
more complete picture of the AEs reported by the study
population. Overall, although AEs were assessed over a
1-year period only, the findings of this study are consist-
ent with previously published long-term safety analyses
of CZP in RA [53].
A key strength of this study is the fact that we compared
safety outcomes for TNFi in U.S. clinical practice using
data from a large, nationwide cohort of patients with RA.
Because patient characteristics and access to biologic
drugs can vary substantially between countries, owing to
payer and regulatory differences, it is important to obtain
clinical evidence directly relevant to practicing rheumatol-
ogists in the United States. It has been demonstrated that
patients in Corrona share similar demographic and clin-
ical characteristics with Medicare beneficiaries with claims
for rheumatology or RA, suggesting that the results we
present may be generalizable to the wider RA population
in the United States [54]. Furthermore, we used PS match-
ing to control for baseline patient characteristics that
might have influenced the decision to treat with CZP or
other TNFi, thereby helping to minimize channeling bias
and allowing for a more accurate comparison of the risk
of AEs associated with these therapies.
Conclusions
In a PS-matched cohort of patients with moderate to se-
vere RA enrolled in the Corrona registry, there were no
differences in the 1-year risk of SIEs, malignancies, and
CVEs between patients treated with CZP and those
treated with other TNFi.
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